| 000 | 01782 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517054612.0 | ||
| 264 | 0 | _c20160909 | |
| 008 | 201609s 0 0 eng d | ||
| 022 | _a2152-2669 | ||
| 024 | 7 |
_a10.1016/j.clml.2015.08.087 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLee, Jung-Hee | |
| 245 | 0 | 0 |
_aA Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma. _h[electronic resource] |
| 260 |
_bClinical lymphoma, myeloma & leukemia _cNov 2015 |
||
| 300 |
_a655-63 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGraft Survival |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xetiology |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma _xdiagnosis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelphalan _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aTransplantation Conditioning |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVidarabine _xadministration & dosage |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aLee, Je-Hwan | |
| 700 | 1 | _aKim, Dae-Young | |
| 700 | 1 | _aSeol, Miee | |
| 700 | 1 | _aLee, Young-Shin | |
| 700 | 1 | _aKang, Young-Ah | |
| 700 | 1 | _aJeon, Mijin | |
| 700 | 1 | _aLee, Kyoo-Hyung | |
| 773 | 0 |
_tClinical lymphoma, myeloma & leukemia _gvol. 15 _gno. 11 _gp. 655-63 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.clml.2015.08.087 _zAvailable from publisher's website |
| 999 |
_c25317004 _d25317004 |
||